Rosetta Cuts Staff, Salaries But Sees No Impact on Timing of Business Initiatives

The cost-cutting moves, which are expected to reduce Rosetta's annual operating costs by $4 million, come less than a month after the Israeli firm unveiled two new microRNA-based tests it has under development and said that it would be establishing its own sales force to market them and certain other of its next-generation products.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories